Rafail Angelos Kotronias1,2, Chun Shing Kwok3,4, Chun Wai Wong3, Tim Kinnaird5, Azfar Zaman6, Mamas A Mamas3,4. 1. Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, UK. rafailkotronias@gmail.com. 2. Oxford University Clinical Academic Graduate School, Oxford University, Oxford, UK. rafailkotronias@gmail.com. 3. Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, UK. 4. Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, UK. 5. University Hospital of Wales, Cardiff, UK. 6. Freeman Hospital and Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, UK.
Abstract
INTRODUCTION: Thienopyridines are a class of antiplatelet drugs widely used in cardiovascular disease prevention and treatment. A recent concern has come to light regarding the safety of thienopyridines because of the possible risk of malignancy. We therefore performed a systematic review and meta-analysis to evaluate the association between thienopyridine exposure and malignancy. METHODS: We searched the MEDLINE and EMBASE databases in March 2016 for studies that evaluated incident cancer and cancer mortality with and without exposure to thienopyridines. Relevant studies were identified, and data were extracted and analysed using random-effects meta-analysis. RESULTS: A total of nine studies (six randomised controlled trials and three cohort studies) that included 282,084 participants were included. The cancer event rate with clopidogrel and prasugrel was 3.25% and 1.58% respectively. When compared with standard aspirin or placebo, thienopyridines are not significantly associated with cancer mortality and event rate (odds ratio [OR] 1.12, 95% confidence interval [CI] 0.80-1.56, n = 3; and OR 0.92, 95% CI 0.52-1.64, n = 2, respectively. Further analyses examining clopidogrel showed no significant association with cancer event rate or malignancy-related death. When comparing prasugrel with clopidogrel, no significant association was noted for cancer event rate (OR 1.10, 95% CI 0.89-1.37, n = 2]. Subanalyses according to cancer location showed that thienopyridines are not significantly associated with malignancy mortality and/or incidence. CONCLUSIONS: Our results suggest that there is currently insufficient evidence to suggest that thienopyridine exposure is associated with an increased risk of cancer event rate or mortality.
INTRODUCTION:Thienopyridines are a class of antiplatelet drugs widely used in cardiovascular disease prevention and treatment. A recent concern has come to light regarding the safety of thienopyridines because of the possible risk of malignancy. We therefore performed a systematic review and meta-analysis to evaluate the association between thienopyridine exposure and malignancy. METHODS: We searched the MEDLINE and EMBASE databases in March 2016 for studies that evaluated incident cancer and cancer mortality with and without exposure to thienopyridines. Relevant studies were identified, and data were extracted and analysed using random-effects meta-analysis. RESULTS: A total of nine studies (six randomised controlled trials and three cohort studies) that included 282,084 participants were included. The cancer event rate with clopidogrel and prasugrel was 3.25% and 1.58% respectively. When compared with standard aspirin or placebo, thienopyridines are not significantly associated with cancer mortality and event rate (odds ratio [OR] 1.12, 95% confidence interval [CI] 0.80-1.56, n = 3; and OR 0.92, 95% CI 0.52-1.64, n = 2, respectively. Further analyses examining clopidogrel showed no significant association with cancer event rate or malignancy-related death. When comparing prasugrel with clopidogrel, no significant association was noted for cancer event rate (OR 1.10, 95% CI 0.89-1.37, n = 2]. Subanalyses according to cancer location showed that thienopyridines are not significantly associated with malignancy mortality and/or incidence. CONCLUSIONS: Our results suggest that there is currently insufficient evidence to suggest that thienopyridine exposure is associated with an increased risk of cancer event rate or mortality.
Authors: Michal Tendera; Victor Aboyans; Marie-Louise Bartelink; Iris Baumgartner; Denis Clément; Jean-Philippe Collet; Alberto Cremonesi; Marco De Carlo; Raimund Erbel; F Gerry R Fowkes; Magda Heras; Serge Kownator; Erich Minar; Jan Ostergren; Don Poldermans; Vincent Riambau; Marco Roffi; Joachim Röther; Horst Sievert; Marc van Sambeek; Thomas Zeller Journal: Eur Heart J Date: 2011-08-26 Impact factor: 29.983
Authors: Jessica Chubak; Evelyn P Whitlock; Selvi B Williams; Aruna Kamineni; Brittany U Burda; Diana S M Buist; Melissa L Anderson Journal: Ann Intern Med Date: 2016-04-12 Impact factor: 25.391
Authors: Matthew T Roe; Derek D Cyr; Debra Eckart; Phillip J Schulte; Michael A Morse; Kimberly L Blackwell; Neal E Ready; S Yousuf Zafar; Anne W Beaven; John H Strickler; Jane E Onken; Kenneth J Winters; Lisa Houterloot; Dmitry Zamoryakhin; Stephen D Wiviott; Harvey D White; Dorairaj Prabhakaran; Keith A A Fox; Paul W Armstrong; E Magnus Ohman Journal: Eur Heart J Date: 2015-12-05 Impact factor: 29.983
Authors: Peter C Elwood; Gareth Morgan; Janet E Pickering; Julieta Galante; Alison L Weightman; Delyth Morris; Mark Kelson; Sunil Dolwani Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240
Authors: Yanhua Wang; Yueping Sun; Ding Li; Lin Zhang; Kemin Wang; Yong Zuo; T Kent Gartner; Junling Liu Journal: PLoS One Date: 2013-11-13 Impact factor: 3.240
Authors: Lucas T Woods; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Gary A Weisman Journal: Biochem Pharmacol Date: 2021-01-04 Impact factor: 5.858
Authors: Loreen Kloss; Claudia Dollt; Kai Schledzewski; Andreas Krewer; Susanne Melchers; Calin Manta; Carsten Sticht; Carolina de la Torre; Jochen Utikal; Viktor Umansky; Astrid Schmieder Journal: Cell Death Dis Date: 2019-10-07 Impact factor: 8.469